Ep1607ihcy

To confirm the cases in our database and determine their individual ground truth, a conventional immunohistochemistry analysis (IHC) analysis was performed for selected cases. The following antibodies were used: Melan-A (Dianova, A103) monoclonal mouse for melanoma^{10 (link)}
in a 1:300 dilution. CD79acy monoclonal mouse anti-human for plasmacytoma (Dako, HM57) in a 1:60 dilution. CK10 (Abcam, EP1607IHCY) monoclonal rabbit for SCC in a 1:1000 dilution. E-Cadherin (Abcam, EP913[2]y) monoclonal rabbit for histiocytoma in a 1:1000 dilution. Briefly, all slides were pretreated using citrate buffer and microwave and signals were visualized using the 3, 3’-diaminobenzidine (DAB) method. As negative control, slides were treated with albumin containing distilled water instead of the primary antibodies. Archive morphologically prototypical tumor was used as positive controls. In the case of trichoblastoma and PNST, IHC was not necessary. In the case of MCT, IHC was not performed because the diagnosis was made by exclusion by comparison with the markers for round cell tumors (plasmacytoma and histiocytoma).

ECs, FBs, PCs, and KCs cultured under xeno‐free conditions were analyzed for surface and intracellular markers expression by flow cytometry and immunofluorescence microscopy using antibodies against: CD31 (WM59; Biolegend), CD45 (2D1; Biolegend), ZO‐1 (sc‐33725; Santa Cruz), VE‐cadherin (sc‐6458; Santa Cruz), vWF (ab201336; abcam) claudin‐5 (34‐1600; Invitrogen), PDGFR‐α (16A1; Biolegend), PDGFR‐β (18A2; Biolegend), CD90 (5E10; Biolegend), NG2 (9.2.27; Invitrogen), a‐SMA (1A4; Invitrogen), FAP (AF3715; Novus Biologics), integrins α2β1 (ab24697; abcam), α5β1 (NBP2‐52680; Novus Biologics), αvβ3 (sc‐7312; Santa Cruz), α6 (MAB13501; R&D systems), α3 (MAB1345; R&D systems), β4 (NBP1‐43369), CK14 (LL002; Novus Biologics), CK10 (EP1607IHCY, abcam), and occludin.